TGOD Exclusive License for CBx Enterprises’ Cannabinoidhttps://web.tmxmoney.com/article.php?newsid=6689635627477856&qm_symbol=ACB (TSX:TGOD) is pleased to announce that the Company has entered into an exclusive agreement with CBx Enterprises LLC for the licensing of the Evolab and CBx Sciences brands and proprietary technologies and formulations within Canada and other international jurisdictions outside of the USA. Based in Colorado, the CBx team brings decades of experience developing and marketing a diverse array of unique, first-to-market medical and recreational cannabis products. The licensing arrangement will immediately expand TGODs product and technology portfolio, and position the Company for the successful development of new products as Canadian and global product requirements and standards rapidly evolve. Evolab is a top cannabinoid vaporization brand that has gained significant market share through the creation of highly differentiated products in a very competitive and saturated market. Evolabs proprietary technologies and industry-leading extraction efficiencies allow for the derivation of pharmaceutical-grade cannabinoid oils and strain-specific terpenes without the use of any harmful solvents or cutting-agents. These technologies and formulations lead to the creation of much cleaner and safer full-plant oils for vaporization without the introduction of chemicals commonly found in the e-vape industry. CBx Sciences has an industry-leading team working tirelessly on the research and development of both new and novel cannabinoids as well as authentic premium quality consumer products. With a focus on identifying synergistic and complimentary botanical ingredients to activate and engage the endocannabinoid system, the research behind each advanced CBx formulation is unmatched in the industry. This focus on research as well as a deep understanding of the commercialization of cannabinoid-based products will allow for the development of product formulations that are tailored to each individual jurisdictions regulatory requirements for both non-psychoactive and psychoactive cannabinoids. TGOD is building an unrivaled global infrastructure for the development and distribution of cutting edge cannabinoid products, said Nicole Smith, CEO, CBx Enterprises. With their distinguished leadership team and recent successful execution of the largest cannabis IPO in history, there is no partner better positioned to rapidly extend the reach of our proven products and technology. This licensing partnership for industry leading technologies and formulations will further allow TGOD to execute on its plans of offering novel and safer delivery methods of both non-psychoactive and psychoactive cannabinoids to patients and consumers around the globe, said Rob Anderson, Co-Chairman and CEO of TGOD. The team at CBx has vast experience in researching and commercializing new and novel consumer products and cannabinoids, and we are excited to be able to offer a platform to take their cutting-edge technologies and advanced formulations worldwide using TGODs premium organic ingredients under TGODs own brand names.